AURA
Aura Biosciences, Inc. NASDAQ Listed Oct 29, 2021$6.86
Pre-mkt
$6.71
-2.19%
Mkt Cap $440.4M
52w Low $4.73
44.3% of range
52w High $9.54
50d MA $7.23
200d MA $6.26
P/E (TTM)
—
EV/EBITDA
—
P/B
3.2x
Debt/Equity
0.1x
ROE
-77.6%
P/FCF
-5.2x
RSI (14)
51.40
ATR (14)
$0.41
Beta
0.35
50d MA
$7.23
200d MA
$6.26
Avg Volume
536.3K
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
80 GUEST STREET · BOSTON, MA 02135 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -0.43 | -0.37 | +14.0% | 6.20 | +3.2% | +7.9% | +0.1% | -2.4% | +2.1% | -0.7% | — |
| Nov 13, 2025 | AMC | -0.46 | -0.40 | +13.0% | 5.53 | -2.4% | +0.0% | -0.5% | -1.6% | -0.2% | -0.9% | — |
| Aug 13, 2025 | AMC | -0.49 | -0.47 | +4.1% | 7.23 | -1.5% | -3.2% | -4.0% | -0.4% | -4.3% | -0.5% | — |
| May 15, 2025 | AMC | -0.47 | -0.55 | -17.0% | 5.18 | -0.6% | +14.9% | -0.5% | +0.2% | +0.5% | -0.3% | — |
| Mar 24, 2025 | AMC | -0.43 | -0.52 | -20.9% | 7.00 | -0.6% | +1.1% | -15.4% | -0.8% | +6.7% | -7.6% | — |
| Nov 12, 2024 | AMC | -0.44 | -0.42 | +4.5% | 10.65 | +3.7% | -3.0% | -3.5% | -5.0% | -3.5% | -2.4% | — |
| Aug 8, 2024 | AMC | -0.45 | -0.41 | +8.9% | 8.47 | -0.2% | -2.0% | -4.0% | +2.3% | -4.5% | +5.1% | — |
| May 9, 2024 | AMC | -0.51 | -0.40 | +21.6% | 7.54 | +1.9% | -3.1% | -1.8% | +4.9% | -0.4% | -4.0% | — |
| Mar 27, 2024 | AMC | -0.39 | -0.50 | -28.2% | 7.70 | +0.0% | +1.9% | -1.1% | -4.6% | -1.4% | -1.8% | — |
| Nov 9, 2023 | AMC | -0.54 | -0.48 | +11.1% | 7.02 | +8.7% | +9.5% | +0.8% | +3.1% | +1.3% | -0.2% | — |
| Aug 9, 2023 | AMC | -0.49 | -0.48 | +2.0% | 11.01 | -0.4% | -2.5% | -0.3% | +0.4% | -5.1% | -2.1% | — |
| May 11, 2023 | AMC | -0.52 | -0.46 | +11.5% | 10.21 | +0.2% | +0.4% | +4.7% | +2.0% | +4.4% | +4.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.27 | $6.30 | +0.5% | -1.1% | +7.9% | +0.1% | -2.4% | +2.1% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.94 | $7.00 | +0.9% | +4.2% | -3.2% | -4.0% | -0.4% | -4.3% |
| May 23 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $5.94 | $5.81 | -2.2% | -0.8% | +1.7% | +0.2% | +1.5% | -3.8% |
| Mar 26 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.08 | $7.04 | -0.6% | -15.4% | -0.8% | +6.7% | -7.6% | -3.2% |
| Mar 26 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $7.08 | $7.04 | -0.6% | -15.4% | -0.8% | +6.7% | -7.6% | -3.2% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.00 | $6.96 | -0.6% | +1.1% | -15.4% | -0.8% | +6.7% | -7.6% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.50 | $7.59 | +1.2% | -6.7% | +1.1% | -15.4% | -0.8% | +6.7% |
| Dec 5 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $8.48 | $8.45 | -0.4% | -2.4% | +8.3% | -2.8% | +2.2% | -2.8% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.33 | $10.47 | +1.4% | -3.5% | -5.0% | -3.5% | -2.4% | -1.9% |
| Oct 18 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $10.29 | $11.45 | +11.3% | +14.1% | -0.8% | -2.2% | +0.1% | -1.4% |
| Oct 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.29 | $11.45 | +11.3% | +14.1% | -0.8% | -2.2% | +0.1% | -1.4% |
| Oct 18 | BTIG | Maintains | Buy → Buy | — | $10.29 | $11.45 | +11.3% | +14.1% | -0.8% | -2.2% | +0.1% | -1.4% |
| Sep 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.79 | $10.25 | +4.7% | +2.9% | -1.0% | -4.0% | -0.2% | +1.5% |
| Sep 13 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $9.79 | $10.25 | +4.7% | +2.9% | -1.0% | -4.0% | -0.2% | +1.5% |
| Aug 28 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.63 | $7.65 | +0.3% | +1.3% | +1.6% | +1.3% | -7.0% | +4.1% |
| Dec 8 | BTIG | Maintains | Buy → Buy | — | $8.63 | $8.55 | -0.9% | +1.4% | -8.5% | +3.7% | +4.3% | +2.1% |
| Nov 10 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.02 | $7.63 | +8.7% | +9.5% | +0.8% | +3.1% | +1.3% | -0.2% |
| Mar 16 | JMP Securities | Maintains | Outperform → Outperform | — | $10.18 | $10.07 | -1.1% | +0.3% | +1.4% | -1.4% | +2.6% | -3.8% |
| Nov 11 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $11.90 | $12.63 | +6.1% | +8.1% | +1.3% | +4.4% | +2.8% | +0.3% |
| Jul 19 | JMP Securities | Maintains | Market Outperform → Outperform | — | $13.69 | $14.24 | +4.0% | +7.7% | -6.9% | +1.2% | -2.1% | +2.1% |
| Nov 23 | BTIG | Maintains | Buy → Buy | — | $19.82 | $19.82 | +0.0% | -9.4% | +11.4% | +13.2% | -21.5% | -1.7% |
| Nov 23 | Evercore ISI | Maintains | Outperform → Outperform | — | $19.82 | $19.82 | +0.0% | -9.4% | +11.4% | +13.2% | -21.5% | -1.7% |
| Nov 23 | SVB Leerink | Maintains | Outperform → Outperform | — | $19.82 | $19.82 | +0.0% | -9.4% | +11.4% | +13.2% | -21.5% | -1.7% |
| Nov 23 | TD Cowen | Maintains | Outperform → Outperform | — | $19.82 | $19.82 | +0.0% | -9.4% | +11.4% | +13.2% | -21.5% | -1.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Gibney Anthony S | See Remarks | Sell | 12,824 | $6.42 | $82K | 265,354 | +0.48% | +0.28% |
| May 7, 2026 | Matrix Capital Management Company, LP10% | — | Sell | 6,922,870 | $5.64 | $39.0M | — | -3.17% | -3.49% |
8-K
Aura Biosciences, Inc. -- 8-K Filing
Aura Biosciences appointed an experienced biopharmaceutical executive as Chief Operating Officer, bringing rare disease development expertise from Hyperion Therapeutics' successful acquisition by Horizon Pharma.
May 4
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
This boilerplate forward-looking statement disclaimer provides no material new information about AURA's operations or financial condition, so investors should disregard this filing as procedurally routine.
Mar 30
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Matrix Capital Management Company, Lp | 6,922,870 | $46M | — | Mar 2026 |
| 2 | Medicxi Ventures Management (Jersey) Ltd | 3,039,892 | $17M | — | Dec 2025 |
| 3 | Vanguard Capital Management Llc | 2,243,828 | $15M | New | Mar 2026 |
| 4 | Franklin Resources Inc | 2,072,726 | $14M | Reduced | Mar 2026 |
| 5 | Millennium Management | 1,097,627 | $7M | Added | Mar 2026 |
| 6 | Northern Trust Corp | 430,522 | $3M | Added | Mar 2026 |
| 7 | Vanguard Portfolio Management Llc | 391,334 | $3M | New | Mar 2026 |
| 8 | Morgan Stanley | 436,814 | $2M | Added | Dec 2025 |
| 9 | Bank Of America Corp /de/ | 125,356 | $839K | Added | Mar 2026 |
| 10 | Ubs Group Ag | 118,904 | $795K | Reduced | Mar 2026 |
| 11 | Platinum Investment Management Ltd | 111,865 | $748K | — | Mar 2026 |
| 12 | Renaissance Technologies Llc | 102,100 | $683K | Reduced | Mar 2026 |
| 13 | Bank Of New York Mellon Corp | 99,433 | $665K | Reduced | Mar 2026 |
| 14 | Quantinno Capital Management Lp | 91,075 | $609K | Added | Mar 2026 |
| 15 | Bnp Paribas Financial Markets | 90,055 | $602K | Reduced | Mar 2026 |
| 16 | Nuveen, Llc | 72,712 | $486K | Added | Mar 2026 |
| 17 | Permanent Capital Management, Lp | 75,864 | $413K | Reduced | Dec 2025 |
| 18 | Tbh Global Asset Management, Llc | 60,322 | $329K | — | Dec 2025 |
| 19 | Aqr Capital Management Llc | 46,143 | $309K | Added | Mar 2026 |
| 20 | Jane Street Group, Llc | 47,431 | $258K | Added | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$440.4M
Enterprise Value
$394.7M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-5.42x
P/B
3.21x
P/S
—
P/FCF
-5.17x
EV/EBITDA
—
Shares Out
64.2M
Financials (TTM)
Revenue
$0
Net Income
-$112.4M
EBITDA
-$111.2M
Free Cash Flow
-$85.2M
Op Cash Flow
-$84.7M
EPS Basic
$-1.76
EPS Diluted
$-1.77
EPS Forward
$-1.61
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$169.4M
Total Liab.
$32.5M
Total Equity
$136.9M
Cash
$59.5M
LT Debt
$14.1M
Book Value/Sh
$2.13
Debt/Equity
0.13x
Current Ratio
8.15
Quick Ratio
8.15
Returns & Growth
ROE
-77.6%
ROA
-62.7%
ROIC
-73.1%
Rev Growth YoY
+0.0%
EPS Growth YoY
-0.6%
Price Returns
2W
-6.4%
1M
+6.0%
3M
+26.8%
6M
+13.2%
12M
+27.5%
Technicals
52W High
$9.54
52W Low
$4.73
50d MA
$7.23
200d MA
$6.26
RSI (14)
51.40
ATR (14)
$0.41
Beta
0.35
Avg Volume
536K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$22.75
High
$25.00
Low
$19.00
Median
$23.50
Data updated apr 24, 2026 7:50pm
· Source: financialmodelingprep.com